Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia

Author： Pea F.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.42, Iss.9, 2003-01, pp. : 851-862

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liposomal daunorubicin + cytarabine effective in AML

By  

Inpharma, Vol. 1, Iss. 1304, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Liposomal daunorubicin + cytarabarine valid for leukaemia?

By  

Inpharma, Vol. 1, Iss. 1413, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Cytarabine/daunorubicin: Aortic thrombosis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1429, 2012-01 ,pp. : 14-15

Adis International

Access to resources Recommend Favorite

Cytarabine/daunorubicin: Neutropenia and hidradenitis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1395, 2012-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: Efficacy and long-term safety in a single institution

By Brion Annie  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1697-1702

Springer Publishing Company

Access to resources Recommend Favorite